by Daniel Gray | Jul 26, 2013 | Press Release
CHF 5074 is a novel, first-in-class small molecule microglia modulator created by Chiesi Final results of a 14-week, double-blind, placebo-controlled Phase 2 study in 96 MCI patients and interim data from the 90-week open-label extension study indicate CHF 5074...
